Evaxion to present new positive data from ongoing phase 2 study on lead vaccine candidate evx-01 at the american society of clinical oncology annual meeting 2024

Copenhagen, denmark, may 23, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announces its participation in the american society of clinical oncology (asco) annual meeting, where it will present positive immune data form its ongoing evx-01 phase 2 study. the study assesses the personalized cancer vaccine evx-01 in combination with anti-pd1 therapy in patients with advanced melanoma. the conference will take place in chicago, il, from may 31 – june 4, 2024.
EVAX Ratings Summary
EVAX Quant Ranking